High-tumor targeted therapeutic engineered cell treatment product as well as preparation and application thereof

By constructing 293T-CD19-scFv target cells and collecting exovesicles, microvesicles or exosomes, the problems of CAR-T cell therapy complexity and over-activation were solved, and targeted killing of CD19 antigen was achieved, reducing the Risk and toxicity, suitable as an efficient tumor treatment product.

CN119082040APending Publication Date: 2024-12-06RUIJIN HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411091927.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-09
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing CAR-T cell treatments are complex in construction, long cycles, require multiple cytokines, are difficult to culture, and excessive activation leads to cytokine release syndrome and inhibitory receptors that affect tumor killing effects.

Method used

Extraves, microvesicles, or exosomes are collected or concentrated as high tumor-targeted therapeutic engineering by constructing 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans target cells Cell therapy product, challenging B-ALL cells expressing CD19 antigen.

Benefits of technology

Achieve the effect of targeted tumor killing, reduces the risk of cytokine storm in patients, simplifies operation, reduces additional damage and risks, and is stable and has low collateral toxicity. It is suitable as a cell-free immunotherapy agent, simplifies the regulatory approval process .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119082040A_ABST
    Figure CN119082040A_ABST
Patent Text Reader

Abstract

The invention relates to a high tumor targeted therapeutic engineered cell therapy product as well as preparation and application thereof. The cell therapy product is obtained by constructing target cells of 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81 trans, and collecting or concentrating target cell culture products. According to the invention, B-ALL cells expressing a CD19 antigen, such as KOPN-8, SEM, NALM6 and the like, are attacked, so that the effect of targeted killing of tumors is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of targeted drugs, and in particular relates to an engineered cell therapy product with high tumor targeting therapeutic properties and its preparation and application. Background Art

[0002] Acute lymphoblastic leukemia (ALL) is a disease in which lymphoid cells in the early stages of differentiation undergo malignant proliferation and can invade the bone marrow, blood, and extramedullary sites. The incidence of the disease is higher in children, especially in children aged 1 to 4 years, and is relatively lower in adults. The emerging immunotherapy CAR-T cell therapy has developed rapidly since the 1990s and has achieved great success and great attention in the treatment of B-cell acute lymphoblastic leukemia (B-ALL). The molecular structure of CAR includes a single-chain antibody fragment (scFv), a hinge region connecting the scFv to the cell membrane, a transmembrane region anchored on the cell membrane, a co-stimulatory domain inside the cell, and a CD3ζ chain. Most of the antigen-binding regions of CAR are derived from the variable light chain (VL) and variable heavy chain (VH) of monoclonal antibodies, which are connected by serine and glycine linker sequences to form scFv, which is an important part of T lymphocytes' specific recognition of tumor antigens. CAR recognizes tumor antigens through scFv and directly transmits signals to T lymphocytes. After activating T cells, T lymphocytes and the cytokines they secrete are responsible for killing tumor cells. Among them, exosomes are a key to the killing function of cytotoxic T cells (CTL).

[0003] Exosomes are small membrane vesicles (40-100 nm) that originate from early endosomes and are secreted by most cell types as a form of extracellular vesicles (EVs) when late endosomes fuse with the plasma membrane. They contain a variety of cellular contents, such as proteins, messenger RNA (mRNA), and microRNA (miRNA), which can be functionally exchanged between cells. The natural ability of exosomes to transfer these biological materials between cells and subsequently regulate biological processes in recipient cells, as well as recent advances in the isolation and purification of these small particles, show their potential as delivery vehicles for genetic materials, proteins, and even small molecules. There are already literatures on the use of exosomes or EVs as drug delivery systems to deliver therapeutic miRNAs. The results showed that exosomes successfully delivered functional miRNAs to targeted cells in vitro and in vivo, and showed favorable biological activities and efficacy, indicating that they are expected to become a new class of drug delivery vehicles. Exosomes are a class of extracellular vesicles (EVs) that play an important role in intercellular communication. Recently, exosomes from immune cells have shown potent anti-tumor activity, similar to their producing cells. For example, dendritic cell-derived exosomes promote tumor cell apoptosis through TNF (tumor necrosis factor-α) superfamily ligands. In addition, natural killer (NK) cell-derived exosomes exert cytotoxic effects on tumor cells by delivering functional NK proteins, namely FasL and perforin. In addition, exosomes from γδ2-T cells contain death-inducing ligands [FasL and TRAIL (TNF-related apoptosis-inducing ligand)], which target and effectively kill human herpesvirus type 4-related tumor cells. CTL-derived exosomes contain CTL surface membrane molecules (CD3, CD8 and TCR), which ensure their targeted attack on tumor cells. The killing effect of CTL is achieved by granzymes, lysosomal enzymes and perforins in exosomes. TCR activation promotes the production of CTL-derived exosomes, and another related study also confirmed the presence of TCR / CD3ζ complexes in the membrane of human CTL-derived exosomes. Based on the biological characteristics of exosomes, exosomes from CAR-T cells may show excellent potential as direct attackers for immunotherapy. Exosomes can be further used for drug delivery due to their functional and structural similarities with synthetic drug carriers like liposomes. CAR exosomes from effector CAR-T cells with cetuximab single-chain variable fragment (scFv) and trastuzumab scFv showed potent antitumor activity with minimal toxicity. Exosomes expressing cetuximab scFv recognized and killed EGFR-positive cells, while exosomes expressing trastuzumab scFv recognized and killed HER-2-positive cells in breast cancer.At the same time, some studies believe that after TCR is activated, the T cell membrane at the immune synapse will quickly form exosomes carrying activated TCRs, which will then fall off and be swallowed by cancer cells, allowing cytotoxic T cells to separate from cancer cells, thus enabling T cells to have the ability to kill continuously. That is, T cells release TCRs in the form of exocytosis, which not only helps T cells break free from the constraints of target cells and allows them to continue killing the enemy, but also terminates the activation signals inside T cells to prevent them from being in an over-activated state, thereby increasing the persistence of CTL cells.

[0004] The current immunotherapy has the following shortcomings: 1. The construction of CAR-T cells is complex and the cycle is long; 2. A relatively mature culture system is required to culture CAR-T cells; 3. Cultivating CAR-T cells requires a variety of cytokines and is expensive; 4. It is difficult to extract T cells from the patient's body and then expand the number of cells in vitro; 5. Because CAR first needs to recognize tumor antigens and then activate T cells before it has a chance to kill tumor cells, there is no exosome killing method that is more direct and effective; 6. CAR-T cells are over-activated and cannot be effectively controlled, which will lead to cytokine release syndrome; 7. T lymphocytes express a variety of inhibitory receptors, including PD-1, TIM-3, TIGIT, LAG-3 and CTLA-4. These inhibitory receptors induce T lymphocyte exhaustion and prevent T lymphocyte activation, thereby affecting the tumor killing effect. Summary of the invention

[0005] The technical problem to be solved by the present invention is to provide an engineered cell therapy product with high tumor targeting therapeutic properties and its preparation and application. The product attacks B-ALL cells expressing CD19 antigen such as KOPN-8, SEM, NALM6, etc., to achieve the effect of targeted tumor killing.

[0006] The present invention provides an engineered cell therapy product with high tumor targeting therapeutic properties. The cell therapy product is obtained by constructing 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans target cells, and collecting or concentrating target cell culture products.

[0007] Furthermore, the product includes exosomes, microvesicles or exosomes.

[0008] Furthermore, the particle size of the exosomes, microvesicles or exosomes is 121.7±2 to 144.0±3 nm.

[0009] Furthermore, the product attacks B-ALL cells expressing CD19 antigen, thereby achieving the effect of targeted tumor killing.

[0010] The present invention also provides a method for preparing an engineered cell therapy product with high tumor targeting therapeutic properties, comprising the following steps:

[0011] (1) 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans viruses were transfected into 293T cells, and stable strains of 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were constructed by cell sorting and used as target cells;

[0012] (2) After culturing the target cells for 48 hours, the cell supernatant was collected, centrifuged to remove the cell precipitate, and filtered;

[0013] (3) The supernatant treated in step (2) was transferred to a Millipore 100 kDa ultrafiltration tube, centrifuged at 5000 rpm at 4°C for 1 h, and the upper concentrated liquid was collected, which is the extracellular vesicles;

[0014] Alternatively, the supernatant treated in step (2) is transferred to a common centrifuge tube and centrifuged at 15000 rpm at 4°C for 30 min, the supernatant is discarded, and the precipitate is resuspended to obtain microvesicles;

[0015] Alternatively, the supernatant treated in step (2) is transferred to an ultracentrifuge tube and centrifuged at 30,000 rpm at 4°C for 2 h. The supernatant is discarded and the precipitate is resuspended to obtain exosomes.

[0016] The present invention also provides an application of an engineered cell therapy product with high tumor targeting therapeutic properties.

[0017] Beneficial Effects

[0018] Compared with the existing CAR-T cell immunotherapy, the cell therapy products of CAR gene therapy have the following main advantages: First, the present invention belongs to a universal tumor-targeting exosome component cell therapy product. They are derived from the body's parental cells and are therefore considered "self". The exosomes infused into the patient's body are non-immunogenic. This adaptive CAR immunotherapy may reduce the risk of cytokine storm in patients. Secondly, there is no need to use the patient's T cells for transformation, and cells from other normal tissues can be replaced, reducing additional harm and risks to patients. Third, only the transmembrane region of the CAR molecule is transformed, and the transformation can be completed by replacing the antigen expression, which is simple to operate. Fourth, the exosome is nanoscale and can cross the tumor barrier, better solving the problem of solid tumors being difficult to overcome. Fifth, the exosome is stable, has a limited lifespan, cannot proliferate, and has a low risk of incidental toxicity. Sixth, the exosome can be used as a cell-free immunotherapy agent, so they should not be considered advanced therapeutic drug products, which may simplify the approval of regulatory agencies. Seventh, the exosome allows "ready-made" production, can be frozen and thawed, and can be used as a ready-made product in a third-party environment. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] Figure 1 aj is the cell transformation map, cell construction positive rate, in vitro killing and apoptosis experiment and cell surface protein CD19 expression of targeted killing of leukemia cells expressing CD19 antigen provided in Example 1.

[0020] Figure 2 This is a flow chart of the method for preparing a cell therapy product that targets and kills leukemia cells expressing the CD19 antigen provided in Example 1.

[0021] Figure 3 The microscopic morphology of four groups of extracellular vesicle samples secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans was observed by transmission electron microscopy.

[0022] Figure 4 The microscopic morphology of four groups of exosome samples secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans was observed by transmission electron microscopy.

[0023] Figure 5 The microscopic morphology of four groups of microvesicle samples secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans was observed by transmission electron microscopy.

[0024] Figure 6 This is a schematic diagram of the particle size characterization of extracellular vesicles (EVs), microvesicles (MVs) and exosomes (EXOs) secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans cells using nanoparticle tracking analysis (NTA).

[0025] Figure 7 This is a schematic diagram of the characterization of the qualitative detection of specific target proteins in three exosome components using Western Blot (WB) technology.

[0026] Figure 8 This is a schematic diagram of the characterization of the qualitative detection of specific target proteins in the three microvesicle components using Western Blot (WB) technology.

[0027] Fig. 9 Flow cytometry was used to label CD81-Beads-FITC and Flag-scFv-APC antibodies to detect the expression of CD81 and Flag-scFv on the extracellular vesicles secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans, and 293T-CD19-scFv-CD81trans.

[0028] Fig.10 It is the mRuby fluorescence expression on the exosomes 293T-CD19-scFv secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans.

[0029] Fig.11 The data are the in vitro killing and apoptosis experiments of the extracellular vesicles (EVs) secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans and various leukemia cells with high expression of CD19 (ad) and the expression of cell surface protein CD19 (eh).

[0030] Fig.12After the four groups of extracellular vesicles secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were co-cultured with leukemia cells with high expression of CD19 for 24h and 48h, the fluorescence expression of the four groups of extracellular vesicles was detected on the leukemia cells.

[0031] Fig.13 The microvesicles (a) and exosomes (b) secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were used to kill and apoptosis various leukemia cells that highly express CD19 in vitro, and the expression of cell surface protein CD19 (c, d). After the microvesicles (e) and exosomes (f) were co-cultured with leukemia cells that highly express CD19, the fluorescence expression on the leukemia cells was detected.

[0032] Fig.14 The morphological changes of exosomes, microvesicles and exosomes secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were captured under a microscope and co-incubated with SEM and KOPN8 leukemia cells for 48 hours.

[0033] Fig.15 The Western Blot (WB) technology was used to detect the changes in CD19 protein expression on the target cell surface and the effects on the PI3K / AKT pathway after the three extracellular vesicle components secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were co-cultured with malignant tumor cells B cells SEM and KOPN8 for 24 hours. DETAILED DESCRIPTION

[0034] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content taught by the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0035] Example 1

[0036] Cell line construction: 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans viruses were transfected into 293T cells, and 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans stable strains were constructed by cell sorting.

[0037] The positive rates of 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were detected by flow cytometry. Since 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans plasmids carry mCherry, the positive rates of stable strains can be detected in the flow PE channel, which are 88%, 90% and 93% respectively. To ensure the completion of stable strain construction, four effector cells, 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans, were co-cultured with a variety of leukemia cells that highly expressed CD19 to detect the in vitro killing apoptosis rate. The co-culture effector-target ratio was 5:1, and the time was 24h and 48h respectively. Cell Trace was used to label 293T cells before co-culture. Since 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans themselves carry mCherry fluorescent protein, they can be distinguished from target cells in flow cytometry, that is, no additional labeling is required. After co-culture, all cells were collected at 24h and 48h, and apoptosis and CD19 expression were detected by flow cytometry after staining with apoptosis antibody Annexin V and CD19 antibody. The experimental results are shown in the figure. Figure 1As shown, the four effector cells of 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were significantly killed after 24 hours of co-culture with leukemia cells SEM, KOPN8, NALM6 and Raji that highly expressed CD19. 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans had stronger killing, and the expression of CD19 on leukemia cells decreased significantly after co-culture. In order to explore the principle of killing, the exosomes, microvesicles and exosomes in the culture medium of the effector cells were extracted and co-cultured with leukemia cells SEM and KOPN8 that highly expressed CD19 to detect their killing ability and whether there was a decrease in CD19 expression. It has been reported in the literature that acute CD19 depletion cannot kill Raji cells, indicating that active CD19 signaling is unnecessary for the survival of Raji cells. Therefore, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans cannot kill Raji cells.

[0038] like Figure 2 As shown, serum without extracellular vesicles, microvesicles and exosomes was prepared, the serum was placed in an ultracentrifuge tube, and centrifuged at 30000rpm 4℃ for 2h for later use. The above cells were cultured with extracellular vesicle-free serum, and the cell supernatant was collected after 48h of cell culture. The cell precipitate was removed for the first time by centrifugation at 300g 4℃, and the supernatant was further centrifuged at 2000g 4℃ to remove excess cell precipitate. The cell supernatant was then filtered using a 0.22μm filter membrane to retain particles of about 220nm in size. Among them, the supernatant was transferred to a Millipore100kDa ultrafiltration tube at 5000rpm 4℃, centrifuged for 1h, and the upper concentrated liquid was collected as the extracellular vesicle, which was stored at -80℃. In addition, the supernatant was transferred to an ordinary centrifuge tube at 15000rpm 4℃ and centrifuged for 30min; the supernatant was discarded, and the precipitate was resuspended in 200μL of DPBS to obtain the microvesicle. Finally, the supernatant was transferred to an ultracentrifuge tube and centrifuged at 30,000 rpm at 4°C for 2 h. The supernatant was discarded and the precipitate was resuspended in 200 μL of DPBS to obtain the exosomes, which were then stored at -80°C. The entire operation was completed on ice.

[0039] After the prepared exosomes, microvesicles and exosomes, the microscopic morphology of the 12 groups of samples was observed using a transmission electron microscope, e.g. Figure 3 , Figure 4 , Figure 5As shown in the figure, exosomes and exosomes are cup-shaped or saucer-shaped, with clear edges and a diameter of about 30 to 150 nm. Microvesicles are spherical or ellipsoidal single or multiple compartment structures formed by closed bilayers. This is consistent with the literature, proving that the microscopic morphology of isolated exosomes, microvesicles, and exosomes is consistent with the theory.

[0040] After the prepared exosomes, microvesicles and exosomes were prepared, the particle concentration and particle size were detected using nanoparticle tracking analysis (NTA). The prepared exosomes, microvesicles and exosomes were taken out of the refrigerator, dissolved on ice, and ultrasonically treated to break up the aggregated particles. The exosomes were diluted to a certain multiple with PBS for sample loading and detection. NTA test results ( Figure 6 ) showed that the diameters of the prepared extracellular vesicles, microvesicles and exosomes particles were between 132-203 nm, which was consistent with the characterization of extracellular vesicles, microvesicles and exosomes.

[0041] After the prepared microvesicles and exosomes, the specific target proteins in the three exosome components were qualitatively detected by Western Blot (WB) technology, such as Figure 7 and Figure 8 As shown, the highly expressed proteins CD9, CD63 and CD81 in extracellular vesicles are highly expressed in microvesicles and exosomes, while the endoplasmic reticulum molecular chaperone protein GRP78 and calnexin are not expressed. This is consistent with the characterization of extracellular vesicles, microvesicles and exosomes.

[0042] Flow cytometry was used to detect the expression of CD81 and Flag-scFv on the extracellular vesicles secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans, and 293T-CD19-scFv-CD81trans. Fig. 9 As shown, using CD63 and CD81 common molecules on exosomes as transmembrane regions, using CD81-Beads-FITC to pre-treat exosomes can show most of the CD81 expressed by exosomes in the form of groups, which is 83.1-95.8%, and the extraction method has high purity. Subsequently, Flag-scFv-APC antibody was used to detect Flag-scFv expression. In order to clarify whether the extracted exosomes contain functional scFv, antibody labeling was used. From the results, it can be seen that the Flag-scFv expression of 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans groups is 89.4-92.4%, that is, the extracted exosomes have high expression of functional scFv.

[0043] Detect the mRuby fluorescence expression on 293T-CD19-scFv cell exosomes. Label the prepared exosomes with Cell Trace-Violet, observe the morphology of Violet-labeled exosomes under a fluorescence microscope, and observe the mRuby fluorescence of 293T-CD19-scFv cell exosomes, that is, the scFv content in the exosomes. Fig.10 As shown, the 293T-CD19-scFv cell exosomes extracted using this protocol contained high expression of scFv.

[0044] The extracellular vesicles (EVs) secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were detected in vitro against a variety of leukemia cells that highly expressed CD19. Fig.11 ad) and cell surface protein CD19 expression ( Fig.11 eh). The results show that the extracellular vesicles of 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans can significantly kill SEM, KOPN8 and NALM6 leukemia cells after 24h and 48h of co-culture, and 293T-CD19-scFv-CD81trans has the most significant killing effect, while Raji cells have no killing effect and are defined as insensitive cells. According to literature reports, CD19 depletion is mediated by target cell endocytosis, so the expression of CD19 on target cells after co-culture was detected. As apoptosis increased, the expression of CD19 decreased. In addition, some literature pointed out that CD19 depletion destroyed the survival of B-ALL target cells by destroying the CD19 / AKT / MYC axis. Therefore, the killing of extracellular vesicles of 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans was due to CD19 depletion and PI3K / AKT pathway.

[0045] While detecting apoptosis, the fluorescence expression of exosomes on target cells was detected after the four groups of exosomes secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were co-cultured with SEM, KOPN8, NALM6 and Raji cells. Fig.12As shown in the figure, it can be concluded from the results that the exosomes secreted by 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans can indeed be detected on the surface of target cells, and the fluorescence persists until 48 hours, which is significantly different from the control group and the 293T group. However, there are differences between different cells, and there is no regularity in which cells can be more strongly targeted by exosomes. Relatively speaking, 293T-CD19-scFv and 293T-CD19-scFv-CD63trans are stronger.

[0046] like Fig.13 As shown, the four groups of microvesicles and exosomes secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were then tested for in vitro killing and apoptosis (a, b), target cell surface protein CD19 expression (c, d) and fluorescence expression of exosomes on target cells (e, f). The results showed that both microvesicles and exosomes had strong anti-tumor effects, especially the microvesicles of 293T-CD19-scFv-CD81trans, which killed about 80% of the tumors in 48 hours, while the microvesicles of 293T-CD19-scFv-CD81trans caused a significant depletion of CD19 (c) and carried more scFv (e), so the killing ability was stronger. In addition, the exosomes of 293T-CD19-scFv-CD63trans killed about 58% of the target cells in 48 hours. We speculate that the reason is that the exosomes of 293T-CD19-scFv-CD63trans have a significant depletion of CD19 (d) and carry more scFv (f), so the killing ability is stronger. Other specific mechanisms need further verification. The microvesicles of 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans can significantly reduce the expression of CD19 on target cells in 48 hours, among which 293T-CD19-scFv-CD81trans has a stronger depletion, while the exosomes of 293T-CD19-scFv-CD63trans lead to a significant depletion of CD19, which corresponds to the stronger killing result.

[0047] The morphological changes of the exosomes, microvesicles and exosomes secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans and SEM and KOPN8 cells after incubation for 48 h were photographed under a microscope. Fig.14As shown in the figure, compared with the PBS control group and the 293T group, the exosomes, microvesicles and exosomes secreted by 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans all had significant killing effects on SEM and KOPN8 cells. Under the microscope, the cells were reduced in size, the connections disappeared, they were separated from the surrounding cells, the nucleus was condensed, the nuclear membrane and nucleoli were broken, and the cell membrane had vesicles, which showed obvious cell death. Among them, 293T-CD19-scFv-CD81trans was the most significant in the exosome and microvesicle groups, and 293T-CD19-scFv-CD81trans was the most obvious in the exosome group.

[0048] In order to further find the specific pathway of killing at the protein level, Western Blot technology was used to detect the changes in target cell CD19 protein and the impact of PI3K / AKT pathway after the extracellular vesicles secreted by 293T, 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were co-cultured with SEM and KOPN8 for 24 hours. As a cell surface signaling protein, CD19 is required for multiple processes involved in B cell development and function, and is therefore crucial for the survival of malignant B cells and a key therapeutic target for B cell malignancies. High expression of CD19 on the surface of malignant cells may activate AKT and upregulate MYC to support the survival of these cells. MYC is one of the key oncoproteins in B cell malignancies, and its dysfunction seems to reduce cell proliferation and evenly induce apoptosis. The levels of phosphorylated AKT and MYC in B-ALL target cells after co-culture with SEM and KOPN8 cells were detected. Fig.15 As shown, in CD19-depleted B-ALL cells, decreased MYC levels were accompanied by a decrease in phosphorylated AKT. These results suggest that CD19 depletion and MYC disruption mediated by extracellular vesicles secreted by 293T-CD19-scFv, 293T-CD19-scFv-CD63trans, and 293T-CD19-scFv-CD81trans cause target cell death primarily by disrupting the CD19 / AKT / MYC axis.

Claims

1. An engineered cell therapy product with high tumor targeting therapeutic properties, characterized in that: The cell therapy product is obtained by constructing 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans target cells and collecting or concentrating the target cell culture products.

2. The cell therapy product according to claim 1, characterized in that: The products include exosomes, microvesicles or exosomes.

3. The cell therapy product according to claim 2, characterized in that: The particle size of the exosomes, microvesicles or exosomes is 121.7±2 to 144.0±3 nm.

4. The cell therapy product according to claim 1, characterized in that: The product attacks B-ALL cells expressing CD19 antigen, achieving the effect of targeted tumor killing.

5. A method for preparing an engineered cell therapy product with high tumor targeting therapeutic properties, comprising the following steps: (1) 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans viruses were transfected into 293T cells, and stable strains of 293T-CD19-scFv, 293T-CD19-scFv-CD63trans and 293T-CD19-scFv-CD81trans were constructed by cell sorting and used as target cells; (2) After culturing the target cells for 48 hours, the cell supernatant was collected, centrifuged to remove the cell precipitate, and filtered; (3) The supernatant treated in step (2) was transferred to a Millipore 100 kDa ultrafiltration tube, centrifuged at 5000 rpm at 4°C for 1 h, and the upper concentrated liquid was collected, which is the extracellular vesicles; Alternatively, the supernatant treated in step (2) is transferred to a common centrifuge tube, centrifuged at 15000 rpm and 4°C for 30 min, the supernatant is discarded, and the precipitate is resuspended to obtain microvesicles; Alternatively, the supernatant treated in step (2) is transferred to an ultracentrifuge tube and centrifuged at 30,000 rpm at 4°C for 2 h. The supernatant is discarded and the precipitate is resuspended to obtain exosomes.

6. An application of the highly tumor-targeted therapeutic engineered cell therapy product as claimed in claim 1.